Astatine-211 labelled therapeutic - ATONCO
Latest Information Update: 30 Jan 2026
At a glance
- Originator Atonco Pharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Triple negative breast cancer
Most Recent Events
- 09 Jan 2026 Early research in Triple-negative-breast-cancer in France (Parenteral)